The Brazilian company Biolab Farmaceutica inaugurates today (Friday, Oct. 20) its first research and development center (R & D) outside Brazil, in the province of Ontario, Canada, where, in three years, it intends to set up a drug production facility.
What Biolab says about itself
”We began our history in 1997, with a team determined to build a success trajectory and legacy. At the present, we are one of the 10 biggest drug companies in Brazil, global market benchmark with solid commitment with science and pharmaceutical industry development in our country. We keep strategic partnerships with companies, universities and research institutes in the whole world, which strength our international representativeness.
Being an expert enterprise that focuses in innovative drugs that are responsible for more than 50% of our revenues, Biolab allies experience and youthfulness to keep on its team dynamic, entrepreneur professionals who anticipate the market needs and dedicate themselves continuously to evolution. We are a live company, committed with the future and, therefore, we invest 10% of our revenues in Research, Development and Innovation.
Leader in the Brazilian drug market under medical prescription in the field of Cardiology, Biolab has a relevant share in the fields of Gynecology, Dermatology, Gastroenterology, Rheumatology, Orthopedics, Pediatrics, among others. Innovative drugs are our center of attention, representing more than 50% of our portfolio, compounded by more than 100 products. We are also meaningfully present in the Skin Care segment, developing products with brand new technology, using resources from Brazilian biodiversity, adapted to the climate and the Brazilian skin.
We have over 2.500 employees and visit monthly 250 thousand doctors in all Brazilian territory, assuring them our friendly presence, besides the continual updating and innovative options.”